Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States

This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquintinib in United States (U.S.) patients to confirm the recommended phase 2 dose (RP2D) established in China. Patients with advanced solid tumors who had progressed on approved sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang-Gillam, Andrea, Schelman, William, Ukrainskyj, Stacey, Chien, Caly, Gonzalez, Martha, Yang, Zhao, Kania, Marek, Yeckes-Rodin, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663261/
https://www.ncbi.nlm.nih.gov/pubmed/37796398
http://dx.doi.org/10.1007/s10637-023-01395-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663261/
https://www.ncbi.nlm.nih.gov/pubmed/37796398
http://dx.doi.org/10.1007/s10637-023-01395-y

Ejemplares similares